NRG Oncology Network Group Operations Center

Nrg Oncology Foundation, Inc., Philadelphia PA

Investigators

Linked publications, trials & patents

Abstract

NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-associated malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. During the project period NRG will continue to develop, activate, and manage multi-center clinical trials that are open for accrual by the NCTN member sites. NRG will also continue to expeditiously publish the results of these trials in peer-reviewed journals. To successfully fulfill these goals, NRG has seven cancer disease site committees, all with internationally recognized multi- disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.